MediPharm Labs Future Growth
Future criteria checks 2/6
MediPharm Labs is forecast to grow earnings and revenue by 71.1% and 23.1% per annum respectively while EPS is expected to grow by 84.5% per annum.
Key information
71.1%
Earnings growth rate
84.5%
EPS growth rate
| Pharmaceuticals earnings growth | 73.7% |
| Revenue growth rate | 23.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 May 2024 |
Recent future growth updates
Recent updates
MediPharm Labs (TSE:LABS) Is Using Debt Safely
May 29
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates
May 23Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year
Jan 11
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 55 | -3 | N/A | N/A | 2 |
| 12/31/2024 | 42 | -9 | N/A | N/A | 1 |
| 3/31/2024 | 37 | -14 | -11 | -11 | N/A |
| 12/31/2023 | 33 | -13 | -13 | -12 | N/A |
| 9/30/2023 | 30 | -16 | -15 | -14 | N/A |
| 6/30/2023 | 28 | -19 | -14 | -14 | N/A |
| 3/31/2023 | 23 | -26 | -14 | -14 | N/A |
| 12/31/2022 | 22 | -30 | -17 | -16 | N/A |
| 9/30/2022 | 22 | -46 | -21 | -20 | N/A |
| 6/30/2022 | 20 | -46 | -18 | -17 | N/A |
| 3/31/2022 | 21 | -48 | -13 | -13 | N/A |
| 12/31/2021 | 22 | -55 | -14 | -13 | N/A |
| 9/30/2021 | 22 | -64 | -17 | -16 | N/A |
| 6/30/2021 | 22 | -72 | -27 | -26 | N/A |
| 3/31/2021 | 30 | -63 | -33 | -28 | N/A |
| 12/31/2020 | 36 | -66 | -45 | -38 | N/A |
| 9/30/2020 | 62 | -39 | -46 | -29 | N/A |
| 6/30/2020 | 101 | -20 | -67 | -40 | N/A |
| 3/31/2020 | 118 | -15 | -74 | -45 | N/A |
| 12/31/2019 | 129 | 2 | -58 | -25 | N/A |
| 9/30/2019 | 107 | 1 | -54 | -27 | N/A |
| 6/30/2019 | 64 | -4 | -36 | -12 | N/A |
| 3/31/2019 | 32 | -8 | -23 | -4 | N/A |
| 12/31/2018 | 10 | -8 | -26 | -11 | N/A |
| 9/30/2018 | N/A | -6 | -23 | -10 | N/A |
| 6/30/2018 | N/A | -4 | -9 | -4 | N/A |
| 3/31/2018 | N/A | -2 | -7 | -3 | N/A |
| 12/31/2017 | N/A | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LABS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LABS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LABS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LABS's revenue (23.1% per year) is forecast to grow faster than the Canadian market (7.2% per year).
High Growth Revenue: LABS's revenue (23.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LABS's Return on Equity is forecast to be high in 3 years time